
## Aubin Moutal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9224924/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	SARS-CoV-2 spike protein co-opts VEGF-A/neuropilin-1 receptor signaling to induce analgesia. Pain, 2021, 162, 243-252.	2.0	119
2	Hierarchical CRMP2 posttranslational modifications control NaV1.7 function. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E8443-E8452.	3.3	103
3	Long-lasting antinociceptive effects of green light in acute and chronic pain in rats. Pain, 2017, 158, 347-360.	2.0	81
4	A membrane-delimited N-myristoylated CRMP2 peptide aptamer inhibits CaV2.2 trafficking and reverses inflammatory and postoperative pain behaviors. Pain, 2015, 156, 1247-1264.	2.0	71
5	CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide. Pain, 2017, 158, 2301-2319.	2.0	67
6	Dysregulation of CRMP2 Post-Translational Modifications Drive Its Pathological Functions. Molecular Neurobiology, 2019, 56, 6736-6755.	1.9	55
7	(S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology. Pain, 2016, 157, 1448-1463.	2.0	54
8	(S)-Lacosamide Binding to Collapsin Response Mediator Protein 2 (CRMP2) Regulates CaV2.2 Activity by Subverting Its Phosphorylation by Cdk5. Molecular Neurobiology, 2016, 53, 1959-1976.	1.9	50
9	Dissecting the role of the CRMP2–neurofibromin complex on pain behaviors. Pain, 2017, 158, 2203-2221.	2.0	50
10	Inhibition of the Ubc9 E2 SUMO-conjugating enzyme–CRMP2 interaction decreases NaV1.7 currents and reverses experimental neuropathic pain. Pain, 2018, 159, 2115-2127.	2.0	49
11	A light-gated potassium channel for sustained neuronal inhibition. Nature Methods, 2018, 15, 969-976.	9.0	47
12	Cdk5-mediated CRMP2 phosphorylation is necessary and sufficient for peripheral neuropathic pain. Neurobiology of Pain (Cambridge, Mass ), 2019, 5, 100022.	1.0	46
13	The prolactin receptor long isoform regulates nociceptor sensitization and opioid-induced hyperalgesia selectively in females. Science Translational Medicine, 2020, 12, .	5.8	46
14	Betulinic acid, derived from the desert lavender Hyptis emoryi, attenuates paclitaxel-, HIV-, and nerve injury–associated peripheral sensory neuropathy via block of N- and T-type calcium channels. Pain, 2019, 160, 117-135.	2.0	44
15	A porcine model of neurofibromatosis type 1 that mimics the human disease. JCI Insight, 2018, 3, .	2.3	44
16	Synaptic zinc inhibition of NMDA receptors depends on the association of GluN2A with the zinc transporter ZnT1. Science Advances, 2020, 6, .	4.7	43
17	Targeting T-type/CaV3.2 channels for chronic pain. Translational Research, 2021, 234, 20-30.	2.2	42
18	Homologyâ€guided mutational analysis reveals the functional requirements for antinociceptive specificity of collapsin response mediator protein 2â€derived peptides. British Journal of Pharmacology, 2018, 175, 2244-2260.	2.7	40

#	Article	IF	CITATIONS
19	The functionalized amino acid (S)-Lacosamide subverts CRMP2-mediated tubulin polymerization to prevent constitutive and activity-dependent increase in neurite outgrowth. Frontiers in Cellular Neuroscience, 2014, 8, 196.	1.8	38
20	Differential neuroprotective potential of CRMP2 peptide aptamers conjugated to cationic, hydrophobic, and amphipathic cell penetrating peptides. Frontiers in Cellular Neuroscience, 2015, 8, 471.	1.8	37
21	Phosphorylated CRMP2 Regulates Spinal Nociceptive Neurotransmission. Molecular Neurobiology, 2019, 56, 5241-5255.	1.9	36
22	CRMP5 Controls Glioblastoma Cell Proliferation and Survival through Notch-Dependent Signaling. Cancer Research, 2015, 75, 3519-3528.	0.4	35
23	CRMP2–Neurofibromin Interface Drives NF1-related Pain. Neuroscience, 2018, 381, 79-90.	1.1	35
24	A single structurally conserved SUMOylation site in CRMP2 controls NaV1.7 function. Channels, 2017, 11, 316-328.	1.5	34
25	Targeting a Potassium Channel/Syntaxin Interaction Ameliorates Cell Death in Ischemic Stroke. Journal of Neuroscience, 2017, 37, 5648-5658.	1.7	33
26	Sustained relief of ongoing experimental neuropathic pain by a CRMP2 peptide aptamer with low abuse potential. Pain, 2016, 157, 2124-2140.	2.0	30
27	Targeting the CaVα–CaVβ interaction yields an antagonist of the N-type CaV2.2 channel with broad antinociceptive efficacy. Pain, 2019, 160, 1644-1661.	2.0	30
28	Novel Compounds Targeting Neuropilin Receptor 1 with Potential To Interfere with SARS-CoV-2 Virus Entry. ACS Chemical Neuroscience, 2021, 12, 1299-1312.	1.7	30
29	CRMP2 is necessary for Neurofibromatosis type 1 related pain. Channels, 2018, 12, 47-50.	1.5	26
30	Reversal of Peripheral Neuropathic Pain by the Small-Molecule Natural Product Physalin F via Block of CaV2.3 (R-Type) and CaV2.2 (N-Type) Voltage-Gated Calcium Channels. ACS Chemical Neuroscience, 2019, 10, 2939-2955.	1.7	26
31	Missense variants in DPYSL5 cause a neurodevelopmental disorder with corpus callosum agenesis and cerebellar abnormalities. American Journal of Human Genetics, 2021, 108, 951-961.	2.6	26
32	CRMP2 Phosphorylation Drives Glioblastoma Cell Proliferation. Molecular Neurobiology, 2018, 55, 4403-4416.	1.9	25
33	Studies on CRMP2 SUMOylation–deficient transgenic mice identify sex-specific Nav1.7 regulation in the pathogenesis of chronic neuropathic pain. Pain, 2020, 161, 2629-2651.	2.0	25
34	Efficacy of (S)-lacosamide in preclinical models of cephalic pain. Pain Reports, 2016, 1, e565.	1.4	24
35	TNF-α mediated upregulation of NaV1.7 currents in rat dorsal root ganglion neurons is independent of CRMP2 SUMOylation. Molecular Brain, 2019, 12, 117.	1.3	23
36	Selective targeting of NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in rodents. Science Translational Medicine, 2021, 13, eabh1314.	5.8	23

#	Article	IF	CITATIONS
37	(â^')-Hardwickiic Acid and Hautriwaic Acid Induce Antinociception via Blockade of Tetrodotoxin-Sensitive Voltage-Dependent Sodium Channels. ACS Chemical Neuroscience, 2019, 10, 1716-1728.	1.7	22
38	Targeted disruption of Kv2.1-VAPA association provides neuroprotection against ischemic stroke in mice by declustering Kv2.1 channels. Science Advances, 2020, 6, .	4.7	21
39	Restoration of Kv7 Channel-Mediated Inhibition Reduces Cued-Reinstatement of Cocaine Seeking. Journal of Neuroscience, 2018, 38, 4212-4229.	1.7	20
40	Genetic and pharmacological antagonism of NK1 receptor prevents opiate abuse potential. Molecular Psychiatry, 2018, 23, 1745-1755.	4.1	20
41	The Natural Flavonoid Naringenin Elicits Analgesia through Inhibition of NaV1.8 Voltage-Gated Sodium Channels. ACS Chemical Neuroscience, 2019, 10, 4834-4846.	1.7	20
42	The role of cyclin-dependent kinase 5 in neuropathic pain. Pain, 2020, 161, 2674-2689.	2.0	20
43	Dysregulation of serum prolactin links the hypothalamus with female nociceptors to promote migraine. Brain, 2022, 145, 2894-2909.	3.7	20
44	Sensitization of Ion Channels Contributes to Central and Peripheral Dysfunction in Neurofibromatosis Type 1. Molecular Neurobiology, 2017, 54, 3342-3349.	1.9	19
45	High Fidelity Cryopreservation and Recovery of Primary Rodent Cortical Neurons. ENeuro, 2018, 5, ENEURO.0135-18.2018.	0.9	18
46	Non-SUMOylated CRMP2 decreases NaV1.7 currents via the endocytic proteins Numb, Nedd4-2 and Eps15. Molecular Brain, 2021, 14, 20.	1.3	17
47	Transcriptional regulation of CRMP5 controls neurite outgrowth through Sox5. Cellular and Molecular Life Sciences, 2018, 75, 67-79.	2.4	16
48	A novel variant in <i>TAF1</i> affects gene expression and is associated with X-linked <i>TAF1</i> intellectual disability syndrome. Neuronal Signaling, 2018, 2, NS20180141.	1.7	16
49	Development and Characterization of An Injury-free Model of Functional Pain in Rats by Exposure to Red Light. Journal of Pain, 2019, 20, 1293-1306.	0.7	15
50	A prolactin-dependent sexually dimorphic mechanism of migraine chronification. Cephalalgia, 2022, 42, 197-208.	1.8	14
51	Druggability of CRMP2 for Neurodegenerative Diseases. ACS Chemical Neuroscience, 2020, 11, 2492-2505.	1.7	13
52	A modulator of the low-voltage-activated T-type calcium channel that reverses HIV glycoprotein 120-, paclitaxel-, and spinal nerve ligation-induced peripheral neuropathies. Pain, 2020, 161, 2551-2570.	2.0	12
53	Coordinating Synaptic Signaling with CRMP2. International Journal of Biochemistry and Cell Biology, 2020, 124, 105759.	1.2	12
54	Heat shock protein Grp78/BiP/HspA5 binds directly to TDP-43 and mitigates toxicity associated with disease pathology. Scientific Reports, 2022, 12, 8140.	1.6	12

#	Article	lF	CITATIONS
55	Assessment of nociception and related quality-of-life measures in a porcine model of neurofibromatosis type 1. Pain, 2019, 160, 2473-2486.	2.0	11
56	Dynamic CRMP2 Regulation of CaV2.2 in the Prefrontal Cortex Contributes to the Reinstatement of Cocaine Seeking. Molecular Neurobiology, 2020, 57, 346-357.	1.9	11
57	Green Light Antinociceptive and Reversal of Thermal and Mechanical Hypersensitivity Effects Rely on Endogenous Opioid System Stimulation. Journal of Pain, 2021, 22, 1646-1656.	0.7	11
58	A Chemical Biology Approach to Model Pontocerebellar Hypoplasia Type 1B (PCH1B). ACS Chemical Biology, 2018, 13, 3000-3010.	1.6	9
59	Putative roles of SLC7A5 (LAT1) transporter in pain. Neurobiology of Pain (Cambridge, Mass ), 2020, 8, 100050.	1.0	9
60	Collapsin Response Mediator Proteins: Novel Targets for Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 77, 949-960.	1.2	9
61	Unconventional Signaling by Extracellular CRMP2: Possible Role as an Atypical Neurotransmitter?. Neuroscience, 2018, 376, 224-226.	1.1	8
62	Defining the Kv2.1–syntaxin molecular interaction identifies a first-in-class small molecule neuroprotectant. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 15696-15705.	3.3	8
63	TAF1-gene editing alters the morphology and function of the cerebellum and cerebral cortex. Neurobiology of Disease, 2019, 132, 104539.	2.1	8
64	Neuronal Conditional Knockout of Collapsin Response Mediator Protein 2 Ameliorates Disease Severity in a Mouse Model of Multiple Sclerosis. ASN Neuro, 2019, 11, 175909141989209.	1.5	8
65	The Effects of Repeated Morphine Treatment on the Endogenous Cannabinoid System in the Ventral Tegmental Area. Frontiers in Pharmacology, 2021, 12, 632757.	1.6	8
66	Chronic pain recruits hypothalamic dynorphin/kappa opioid receptor signalling to promote wakefulness and vigilance. Brain, 2023, 146, 1186-1199.	3.7	8
67	Differential expression of Cdk5-phosphorylated CRMP2 following a spared nerve injury. Molecular Brain, 2020, 13, 97.	1.3	7
68	Conditional knockout of CRMP2 in neurons, but not astrocytes, disrupts spinal nociceptive neurotransmission to control the initiation and maintenance of chronic neuropathic pain. Pain, 2022, 163, e368-e381.	2.0	7
69	Alternaria alternata-induced airway epithelial signaling and inflammatory responses via protease-activated receptor-2 expression. Biochemical and Biophysical Research Communications, 2022, 591, 13-19.	1.0	7
70	Activity of T-type calcium channels is independent of CRMP2 in sensory neurons. Channels, 2019, 13, 147-152.	1.5	6
71	The investigation of the T-type calcium channel enhancer SAK3 in an animal model of TAF1 intellectual disability syndrome. Neurobiology of Disease, 2020, 143, 105006.	2.1	5
72	Conotoxin contulakin-G engages a neurotensin receptor 2/R-type calcium channel (Cav2.3) pathway to mediate spinal antinociception. Pain, 2022, 163, 1751-1762.	2.0	5

#	Article	IF	CITATIONS
73	Comparison of quinazoline and benzoylpyrazoline chemotypes targeting the CaVα-β interaction as antagonists of the N-type CaV2.2 channel. Channels, 2021, 15, 128-135.	1.5	4
74	Stereospecific Effects of Benzimidazolonepiperidine Compounds on T-Type Ca <sup>2+</sup> Channels and Pain. ACS Chemical Neuroscience, 2022, 13, 2035-2047.	1.7	4
75	1-O-Acetylgeopyxin A, a derivative of a fungal metabolite, blocks tetrodotoxin-sensitive voltage-gated sodium, calcium channels and neuronal excitability which correlates with inhibition of neuropathic pain. Molecular Brain, 2020, 13, 73.	1.3	3
76	Evaluation of edonerpic maleate as a CRMP2 inhibitor for pain relief. Channels, 2019, 13, 498-504.	1.5	2
77	Evaluation of the effects of the T-type calcium channel enhancer SAK3 in a rat model of TAF1 deficiency. Neurobiology of Disease, 2021, 149, 105224.	2.1	1
78	(399) A membrane-delimited N-myristoylated CRMP2 peptide aptamer inhibits CaV2.2 trafficking and reverses post-operative pain behaviors. Journal of Pain, 2015, 16, S75.	0.7	0